HealthWorld

Asia Pacific RNAi therapeutics market Growth Analysis, Key Company Profiles & Demand Forecasts to 2027

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.

Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Asia Pacific.

Request Sample Copy Of this Report @ https://www.theinsightpartners.com/sample/TIPRE00015147/

 

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Asia Pacific RNAi Therapeutics market during the forecast period.

Asia Pacific RNAi Therapeutics Market Segmentation

 

By Molecule Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

 

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

 

By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

 

Purchase Copy of this Report @   https://www.theinsightpartners.com/buy/TIPRE00015147/

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders, such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in June 2020, OliX Pharmaceuticals signed an agreement with LGC Biosearch technologies to accelerate production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures made a private investment in public Australia based biotech Benitec Biopharma. Furthermore, Benitech and NantVentures, with the help of NantWorks, plan to begin an oncology-focused R&D collaboration with clinical development and preclinical evaluation that is to be led by Benitec. Moreover, in July 2018, Axovant Sciences signed a gene therapy licensing and development deal with Benitec Biopharma. As part of the deal, Axovant Sciences made an upfront payment of US$ 10 million to Benitec, which is also eligible for additional payments based on regulatory, development, and commercial sales milestones. Such investments help biotech and pharma companies not only launch new products but also increase number of approved products. The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

Back to top button